Page 299 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C1.8. Tumor characteristics—Gleason score (continued)
Author Database Gleason score 1980- 1985- 1990- 1995- 2000- 2005- Statistical Notes
Year groups 1984 1989 1994 1999 2004 2010 analysis
PMID
68
Cooperberg CaPSURE 2-4 40.8% 17.4% 1.3% 0.7% P<0.001 Information on
2007 5 26.4% 24.9% 4.9% 2.3% (“trend in trends was
17644125 6 32.9% 57.7% 93.8% 97.0% distribution of reported only for
(1990-94) (1995- (2002- (2004- each risk patients with
99) 03) 06) characteristic”) “low-risk”
prostate cancer,
defined as
PSA≤10 ng/ml,
Gleason score≤6
and clinical stage
T1 or T2a.
90
Cooperberg CaPSURE 2 - 6 60.1% 48.5% 33.9% 26.1% High risk
2008 3 + 4 13.1% 18.7% 19.7% 20.9% P<0.001 localized prostate
18369637 4 + 3 4.3% 9.2% 11.8% 12.1% (Cuzick test for cancer only
8 - 10 22.5% 23.7% 34.6% 40.8% trend)
(1990-94) (1995- (2002- (2004-
99) 03) 07)
71
Greene CaPSURE 2-4 3% 1% P=0.006
2005 5-6 66% 66% (chi-square
16194711 7 24% 26% comparing 2
8-10 6% 7% periods)
(1997- (2000-
99) 03)
73
Mettlin NCDB Well diff. 31.3% 19.8% NR Limited to men
1996 Moderately diff. 38.6% 57.5% with known tumor
8640686 Poorly diff. 30.1% 22.8 % grade (the
(1986) (1993) proportion of
unknown grade
declined over
time, from 18.3%
in 1986 to 10.2%
in 1993).
75
Mettlin NCDB Well diff. 21.8% 15.8% NR
1998 Moderately diff. 55.6% 62.2%
9781963 Poorly diff. 21.5% 21.2%
Undifferentiated 1.1% 0.7%
(1992) (1995)

C-67